Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

Up­stream Bio has raised an­oth­er $200 mil­lion to go through Phase II stud­ies and pre­pare for late-stage tri­als of an ex-Astel­las mon­o­clon­al an­ti­body in an­tic­i­pa­tion of com­pe­ti­tion with As­traZeneca and Am­gen’s asth­ma drug Tezspire.

The raise, dis­closed Thurs­day morn­ing, mir­rors its first fund­ing round from 2021 that bankrolled the Waltham, MA-based start­up’s on­go­ing Phase Ib in asth­ma. It plans to use the new round to sup­port mid-stage stud­ies in both asth­ma and chron­ic rhi­nos­i­nusi­tis with nasal polyps. Both of those stud­ies will kick off in the first quar­ter of 2024, CEO Saman­tha Truex told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER